These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7976226)

  • 1. Eosinophilia myalgia syndrome: absence of immunoglobulin reactivity suggests a cellular rather than humoral mechanism.
    Villanova M; De Clerck LS; Cras P; Guazzi GC; Martin JJ
    Acta Neurol Belg; 1994; 94(3):200-4. PubMed ID: 7976226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophilia-myalgia syndrome: a clinicopathological study of four patients.
    Villanova M; De Clerck LS; Cras P; Ceuterick C; Van Marck E; Guazzi GC; Martin JJ
    Clin Neuropathol; 1993; 12(4):201-3. PubMed ID: 8403629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Eosinophilia-myalgia syndrome].
    Kotake S; Kashiwazaki S
    Nihon Rinsho; 1992 Jul; 50(7):1650-5. PubMed ID: 1404896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophilia myalgia syndrome: I. Immunocytochemical evidence for a T-cell-mediated immune effector response.
    Emslie-Smith AM; Engel AG; Duffy J; Bowles CA
    Ann Neurol; 1991 May; 29(5):524-8. PubMed ID: 1859182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic immune activation in the eosinophilia-myalgia syndrome.
    McKinley KL; Harati Y; Schneider LW
    Muscle Nerve; 1993 Sep; 16(9):947-51. PubMed ID: 8355725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilia-myalgia syndrome in Wisconsin.
    Butler JC; Davis JP
    Wis Med J; 1990 Dec; 89(12):687-91. PubMed ID: 2293489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements.
    Clauw DJ; Flockhart DA; Mullins W; Katz P; Medsger TA
    J Rheumatol; 1994 Dec; 21(12):2385-7. PubMed ID: 7699648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polyneuropathy and fasciitis in eosinophilia-myalgia syndrome].
    Hetzel W; Dangel P; Molitor H
    Fortschr Neurol Psychiatr; 1991 Oct; 59(10):425-31. PubMed ID: 1662183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinophilia-myalgia syndrome and fasciitis with an active alveolitis.
    Chauhan D; Mengel CE
    Kans Med; 1993 Jun; 94(6):175-7. PubMed ID: 8355447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The eosinophilia-myalgia syndrome and eosinophilic fasciitis.
    Jimenez SA; Varga J
    Curr Opin Rheumatol; 1991 Dec; 3(6):986-94. PubMed ID: 1772754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).
    Silver RM; Ludwicka A; Hampton M; Ohba T; Bingel SA; Smith T; Harley RA; Maize J; Heyes MP
    J Clin Invest; 1994 Apr; 93(4):1473-80. PubMed ID: 8163652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
    Horwitz RI; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():60-72. PubMed ID: 8895182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome.
    Kilbourne EM; Philen RM; Kamb ML; Falk H
    J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal models of the eosinophilia-myalgia syndrome.
    Clauw DJ
    J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
    Zangrilli JG; Mayeno AN; Vining V; Varga J
    Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibromyalgia, psychiatric disorders, and assessment of the longterm outcome of eosinophilia-myalgia syndrome.
    Hudson JI; Pope HG; Carter WP; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():37-42; discussion 42-3. PubMed ID: 8895180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms.
    Brenneman DE; Page SW; Schultzberg M; Thomas FS; Zelazowski P; Burnet P; Avidor R; Sternberg EM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):1029-35. PubMed ID: 8355179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina.
    Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T
    Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.